Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för Daniel M Junius. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att Daniel M Junius har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:IDXX / IDEXX Laboratories, Inc. | Director | 3 304 |
US:GLYC / GlycoMimetics, Inc. | Director | 98 459 |
US:IMGN / ImmunoGen, Inc. | Director | 113 518 |
US:VTAE / Vitae Pharmaceuticals, Inc. | Director | 0 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av Daniel M Junius. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av Daniel M Junius som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-05-14 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
S - Sale | −2 683 | 3 304 | −44,81 | 506,41 | −1 358 697 | 1 673 178 | |
2025-05-14 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
M - Exercise | 1 279 | 5 987 | 27,17 | 283,59 | 362 712 | 1 697 853 | |
2025-05-14 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
M - Exercise | 1 404 | 4 708 | 42,49 | 245,79 | 345 089 | 1 157 179 | |
2025-05-08 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
M - Exercise | 262 | 3 304 | 8,61 | ||||
2024-04-02 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
A - Award | 5 209 | 98 459 | 5,59 | 3,00 | 15 627 | 295 377 | |
2024-02-01 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 14 | 3 042 | 0,46 | 521,03 | 7 294 | 1 584 973 | |
2023-11-01 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 19 | 3 028 | 0,63 | 396,39 | 7 531 | 1 200 269 | |
2023-08-01 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 14 | 3 009 | 0,47 | 552,78 | 7 739 | 1 663 315 | |
2023-05-11 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
P - Purchase | 30 000 | 93 250 | 47,43 | 1,56 | 46 800 | 145 470 | |
2023-05-02 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 13 | 2 995 | 0,44 | 492,16 | 6 398 | 1 474 019 | |
2023-02-17 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
S - Sale | −2 187 | 2 982 | −42,31 | 511,68 | −1 119 044 | 1 525 829 | |
2023-02-17 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
M - Exercise | 2 187 | 5 169 | 73,34 | 206,62 | 451 878 | 1 068 019 | |
2023-02-01 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 14 | 2 982 | 0,47 | 482,95 | 6 761 | 1 440 157 | |
2022-12-07 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
S - Sale | −3 046 | 2 968 | −50,65 | 424,91 | −1 294 276 | 1 261 133 | |
2022-12-07 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
M - Exercise | 3 046 | 6 014 | 102,63 | 160,28 | 488 213 | 963 924 | |
2022-11-18 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
P - Purchase | 20 000 | 63 250 | 46,24 | 1,87 | 37 400 | 118 278 | |
2022-11-01 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 18 | 2 968 | 0,61 | 364,28 | 6 557 | 1 081 183 | |
2022-08-02 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 16 | 2 950 | 0,55 | 399,18 | 6 387 | 1 177 581 | |
2022-05-20 |
|
4 | GLYC |
GLYCOMIMETICS INC
Stock Option (right to buy) |
A - Award | 21 000 | 21 000 | |||||
2022-05-13 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Non-Qualified Stock Option (right-to-buy) |
A - Award | 945 | 945 | |||||
2022-05-13 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Deferred Stock Unit |
A - Award | 344 | 344 | |||||
2022-05-03 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 15 | 2 934 | 0,51 | 430,48 | 6 457 | 1 263 028 | |
2022-02-01 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 13 | 2 919 | 0,45 | 489,05 | 6 358 | 1 427 537 | |
2021-11-02 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 10 | 2 906 | 0,35 | 666,14 | 6 661 | 1 935 803 | |
2021-08-12 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Non-Qualified Stock Option (right-to-buy) |
M - Exercise | −2 402 | 0 | −100,00 | ||||
2021-08-12 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
S - Sale | −2 402 | 2 896 | −45,34 | 679,58 | −1 632 355 | 1 968 069 | |
2021-08-12 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
M - Exercise | 2 402 | 5 298 | 82,94 | 85,00 | 204 170 | 450 330 | |
2021-08-03 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 10 | 2 896 | 0,35 | 678,53 | 6 785 | 1 965 023 | |
2021-05-27 |
|
4 | GLYC |
GLYCOMIMETICS INC
Stock Option (right to buy) |
A - Award | 10 500 | 10 500 | |||||
2021-05-27 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
A - Award | 5 250 | 43 250 | 13,82 | ||||
2021-05-24 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Non-Qualified Stock Option (right-to-buy) |
M - Exercise | −2 500 | 2 402 | −51,00 | ||||
2021-05-24 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
S - Sale | −2 500 | 2 886 | −46,42 | 539,57 | −1 348 918 | 1 557 191 | |
2021-05-24 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
M - Exercise | 2 500 | 5 386 | 86,63 | 85,00 | 212 500 | 457 810 | |
2021-05-14 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Non-Qualified Stock Option (right-to-buy) |
A - Award | 723 | 723 | |||||
2021-05-14 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Deferred Stock Unit |
A - Award | 224 | 3 387 | 7,08 | ||||
2021-05-04 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 11 | 2 886 | 0,38 | 548,99 | 6 039 | 1 584 385 | |
2021-02-24 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Non-Qualified Stock Option (right-to-buy) |
M - Exercise | −1 000 | 4 902 | −16,94 | ||||
2021-02-24 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Incentive Stock Option (right-to-buy) |
M - Exercise | −898 | 0 | −100,00 | ||||
2021-02-24 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
S - Sale | −1 888 | 2 875 | −39,64 | 538,57 | −1 016 815 | 1 548 381 | |
2021-02-24 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
S - Sale | −10 | 4 763 | −0,21 | 539,19 | −5 392 | 2 568 162 | |
2021-02-24 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
M - Exercise | 1 000 | 4 773 | 26,50 | 85,00 | 85 000 | 405 705 | |
2021-02-24 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
M - Exercise | 898 | 3 773 | 31,23 | 79,54 | 71 427 | 300 104 | |
2021-02-03 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 13 | 2 875 | 0,45 | 478,68 | 6 223 | 1 376 205 | |
2020-11-02 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 15 | 2 862 | 0,53 | 424,82 | 6 372 | 1 215 835 | |
2020-08-21 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Non-Qualified Stock Option (right-to-buy) |
M - Exercise | −3 722 | 0 | −100,00 | ||||
2020-08-21 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
S - Sale | −3 722 | 2 847 | −56,66 | 382,61 | −1 424 063 | 1 089 282 | |
2020-08-21 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
M - Exercise | 3 722 | 6 569 | 130,73 | 63,95 | 238 022 | 420 088 | |
2020-08-03 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 13 | 2 847 | 0,46 | 371,10 | 4 824 | 1 056 522 | |
2020-05-27 |
|
4 | GLYC |
GLYCOMIMETICS INC
Stock Option (right to buy) |
A - Award | 21 000 | 21 000 | |||||
2020-05-20 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Non-Qualified Stock Option (right-to-buy) |
M - Exercise | −4 000 | 3 422 | −53,89 | ||||
2020-05-20 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
S - Sale | 4 000 | 2 834 | −343,05 | 295,61 | 1 182 433 | 837 754 | |
2020-05-20 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
M - Exercise | 4 000 | 6 834 | 141,14 | 63,95 | 255 800 | 437 034 | |
2020-05-08 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Non-Qualified Stock Option (right-to-buy) |
A - Award | 1 279 | 1 279 | |||||
2020-05-08 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Deferred Stock Unit |
A - Award | 370 | 3 163 | 13,25 | ||||
2020-03-10 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
P - Purchase | 20 000 | 38 000 | 111,11 | 3,40 | 68 000 | 129 200 | |
2020-02-03 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 22 | 2 834 | 0,78 | 283,73 | 6 242 | 804 091 | |
2019-10-31 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 23 | 2 812 | 0,82 | 273,85 | 6 299 | 770 066 | |
2019-08-15 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
P - Purchase | 10 000 | 18 000 | 125,00 | 3,18 | 31 800 | 57 240 | |
2019-08-01 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 22 | 2 789 | 0,80 | 286,05 | 6 293 | 797 793 | |
2019-05-21 |
|
4 | GLYC |
GLYCOMIMETICS INC
Stock Option (right to buy) |
A - Award | 21 000 | 21 000 | |||||
2019-05-10 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Non-Qualified Stock Option (right-to-buy) |
A - Award | 1 404 | 1 404 | |||||
2019-05-10 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Deferred Stock Unit |
A - Award | 427 | 2 793 | 18,05 | ||||
2019-05-02 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 26 | 2 767 | 0,95 | 232,00 | 6 032 | 641 944 | |
2019-02-01 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 29 | 2 741 | 1,07 | 207,68 | 6 023 | 569 251 | |
2018-11-01 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 28 | 2 712 | 1,04 | 210,22 | 5 886 | 570 117 | |
2018-08-01 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 25 | 2 684 | 0,94 | 237,76 | 5 944 | 638 148 | |
2018-05-21 |
|
4 | GLYC |
GLYCOMIMETICS INC
Stock Option (right to buy) |
A - Award | 11 000 | 11 000 | |||||
2018-05-11 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Non-Qualified Stock Option (right-to-buy) |
A - Award | 2 187 | 2 187 | |||||
2018-05-11 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Deferred Stock Unit |
A - Award | 224 | 2 366 | 10,46 | ||||
2018-05-02 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 31 | 2 659 | 1,18 | 194,49 | 6 029 | 517 149 | |
2018-03-16 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −25 000 | 113 518 | −18,05 | 4,29 | −107 250 | 486 992 | |
2018-03-16 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
S - Sale | −25 000 | 184 987 | −11,91 | 12,02 | −300 405 | 2 222 841 | |
2018-03-16 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | 25 000 | 209 987 | 13,51 | 4,29 | 107 250 | 900 844 | |
2018-03-02 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Non-Qualified Stock Option (right-to-buy) |
M - Exercise | −2 974 | 0 | −100,00 | ||||
2018-03-02 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
S - Sale | −2 974 | 2 628 | −53,09 | 190,06 | −565 232 | 499 472 | |
2018-03-02 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
M - Exercise | 2 974 | 5 602 | 113,17 | 64,69 | 192 388 | 362 393 | |
2018-02-23 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
S - Sale | −11 713 | 184 987 | −5,95 | 12,00 | −140 556 | 2 219 844 | |
2018-02-21 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
S - Sale | −25 000 | 196 700 | −11,28 | 11,68 | −292 000 | 2 297 456 | |
2018-02-20 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −25 000 | 163 518 | −13,26 | 4,29 | −107 250 | 701 492 | |
2018-02-20 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | 25 000 | 221 700 | 12,71 | 4,29 | 107 250 | 951 093 | |
2018-02-14 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −46 667 | 0 | −100,00 | 3,30 | −154 001 | ||
2018-02-14 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
S - Sale | −46 667 | 196 700 | −19,18 | 10,01 | −467 253 | 1 969 459 | |
2018-02-14 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | 46 667 | 243 367 | 23,72 | 3,30 | 154 001 | 803 111 | |
2018-02-01 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 32 | 2 628 | 1,23 | 186,59 | 5 971 | 490 359 | |
2017-11-01 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 36 | 2 596 | 1,41 | 164,41 | 5 919 | 426 808 | |
2017-07-31 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 35 | 2 560 | 1,39 | 167,52 | 5 863 | 428 851 | |
2017-06-16 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
A - Award | 3 000 | 8 000 | 60,00 | 11,27 | 33 810 | 90 160 | |
2017-06-15 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
A - Award | 10 000 | 10 000 | 4,64 | 46 400 | 46 400 | ||
2017-06-15 |
|
4 | IMGN |
IMMUNOGEN INC
Deferred Share Unit |
A - Award | 3 000 | 4 500 | 200,00 | ||||
2017-05-30 |
|
4 | GLYC |
GLYCOMIMETICS INC
Stock Option (right to buy) |
A - Award | 11 000 | 11 000 | |||||
2017-05-05 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Non-Qualified Stock Option (right-to-buy) |
A - Award | 3 046 | 3 046 | |||||
2017-05-05 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Deferred Stock Unit |
A - Award | 289 | 2 142 | 15,60 | ||||
2017-05-01 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 30 | 2 525 | 1,20 | 167,73 | 5 032 | 423 518 | |
2017-02-09 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Non-Qualified Stock Option (right-to-buy) |
M - Exercise | −3 000 | 2 964 | −50,30 | ||||
2017-02-09 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
S - Sale | −3 000 | 2 495 | −54,60 | 141,75 | −425 264 | 353 677 | |
2017-02-09 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
M - Exercise | 3 000 | 5 495 | 120,24 | 64,69 | 194 070 | 355 472 | |
2017-01-31 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 41 | 2 495 | 1,67 | 120,50 | 4 940 | 300 648 | |
2016-12-21 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
P - Purchase | 5 000 | 5 000 | 6,01 | 30 050 | 30 050 | ||
2016-12-13 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
A - Award | 5 000 | 5 000 | 1,84 | 9 200 | 9 200 | ||
2016-12-13 |
|
4 | IMGN |
IMMUNOGEN INC
Deferred Share Unit |
A - Award | 1 500 | 1 500 | |||||
2016-10-31 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 48 | 2 454 | 2,00 | 105,05 | 5 042 | 257 793 | |
2016-10-25 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Stock Option (Right to Buy) |
D - Sale to Issuer | −20 000 | 0 | −100,00 | 9,63 | −192 600 | ||
2016-08-02 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 53 | 2 406 | 2,25 | 93,79 | 4 971 | 225 659 | |
2016-07-27 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Stock Option (Right to Buy) |
A - Award | 20 000 | 20 000 | |||||
2016-06-02 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −27 085 | 0 | −100,00 | 3,19 | −86 401 | ||
2016-06-02 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | 27 085 | 196 700 | 15,97 | 3,19 | 86 401 | 627 473 | |
2016-05-19 |
|
4 | GLYC |
GLYCOMIMETICS INC
Stock Option (right to buy) |
A - Award | 11 000 | 11 000 | |||||
2016-05-06 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Non-Qualified Stock Option (right-to-buy) |
A - Award | 5 902 | 5 902 | |||||
2016-05-06 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Deferred Stock Unit |
A - Award | 515 | 1 853 | 38,49 | ||||
2016-05-03 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 59 | 2 353 | 2,57 | 84,35 | 4 977 | 198 476 | |
2016-03-21 |
|
4 | GLYC |
GLYCOMIMETICS INC
Stock Option (right to buy) |
A - Award | 22 000 | 22 000 | |||||
2016-03-21 | 3 | GLYC |
GLYCOMIMETICS INC
No securities beneficially owned |
0 | ||||||||
2016-02-02 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 71 | 2 294 | 3,19 | 70,14 | 4 980 | 160 901 | |
2016-01-04 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −5 416 | 27 085 | −16,66 | 3,19 | −17 277 | 86 401 | |
2016-01-04 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
S - Sale | X | −5 416 | 169 615 | −3,09 | 13,17 | −71 349 | 2 234 474 |
2016-01-04 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | X | 5 416 | 175 031 | 3,19 | 3,19 | 17 277 | 558 349 |
2015-12-21 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
G - Gift | −1 003 | 169 615 | −0,59 | ||||
2015-12-01 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −5 416 | 32 501 | −14,28 | 3,19 | −17 277 | 103 678 | |
2015-12-01 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
S - Sale | X | −5 416 | 170 618 | −3,08 | 13,11 | −71 025 | 2 237 467 |
2015-12-01 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | X | 5 416 | 176 035 | 3,17 | 3,19 | 17 277 | 561 552 |
2015-11-04 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −5 907 | 188 518 | −3,04 | 4,29 | −25 341 | 808 742 | |
2015-11-04 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | 5 907 | 170 618 | 3,59 | 4,29 | 25 341 | 731 951 | |
2015-11-03 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 73 | 2 223 | 3,40 | 68,62 | 5 009 | 152 542 | |
2015-11-03 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −5 497 | 37 917 | −12,66 | 3,19 | −17 535 | 120 955 | |
2015-11-03 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
S - Sale | X | −5 497 | 159 812 | −3,33 | 12,00 | −65 964 | 1 917 744 |
2015-11-03 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | X | 5 497 | 165 309 | 3,44 | 3,19 | 17 535 | 527 336 |
2015-11-03 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −122 | 62 669 | −0,19 | 5,77 | −704 | 361 600 | |
2015-11-03 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −5 575 | 194 425 | −2,79 | 4,29 | −23 917 | 834 083 | |
2015-11-03 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | 122 | 159 812 | 0,08 | 5,77 | 704 | 922 115 | |
2015-11-03 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | 5 575 | 159 690 | 3,62 | 4,29 | 23 917 | 685 070 | |
2015-10-30 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −5 335 | 43 414 | −10,94 | 3,19 | −17 019 | 138 491 | |
2015-10-30 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
S - Sale | −5 335 | 154 115 | −3,35 | 12,01 | −64 072 | 1 850 875 | |
2015-10-30 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | X | 5 335 | 159 450 | 3,46 | 3,19 | 17 019 | 508 646 |
2015-09-09 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −4 899 | 62 791 | −7,24 | 5,77 | −28 267 | 362 304 | |
2015-09-09 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | 4 899 | 159 014 | 3,18 | 5,77 | 28 267 | 917 511 | |
2015-09-01 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −5 416 | 48 749 | −10,00 | 3,19 | −17 277 | 155 509 | |
2015-09-01 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
S - Sale | −5 416 | 154 115 | −3,39 | 13,15 | −71 238 | 2 027 121 | |
2015-09-01 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | X | 5 416 | 159 531 | 3,51 | 3,19 | 17 277 | 508 904 |
2015-08-18 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −12 310 | 67 690 | −15,39 | 5,77 | −71 029 | 390 571 | |
2015-08-18 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | 12 310 | 154 115 | 8,68 | 5,77 | 71 029 | 889 244 | |
2015-08-05 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
P - Purchase | 1 000 | 2 150 | 86,96 | 73,15 | 73 150 | 157 272 | |
2015-08-04 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −5 416 | 54 165 | −9,09 | 3,19 | −17 277 | 172 786 | |
2015-08-04 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
S - Sale | −5 416 | 141 805 | −3,68 | 17,03 | −92 247 | 2 415 279 | |
2015-08-04 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | X | 5 416 | 147 221 | 3,82 | 3,19 | 17 277 | 469 635 |
2015-08-03 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 70 | 1 150 | 6,48 | 71,34 | 4 994 | 82 041 | |
2015-07-14 |
|
4 | IMGN |
IMMUNOGEN INC
Stock option (right to buy) |
A - Award | 205 000 | 205 000 | 16,72 | 3 427 600 | 3 427 600 | ||
2015-07-02 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −5 416 | 59 584 | −8,33 | 3,19 | −17 277 | 190 073 | |
2015-07-02 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
S - Sale | −5 416 | 141 805 | −3,68 | 14,34 | −77 676 | 2 033 767 | |
2015-07-02 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | X | 5 416 | 147 221 | 3,82 | 3,19 | 17 277 | 469 635 |
2015-05-11 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −1 215 | 0 | −100,00 | 5,74 | −6 974 | ||
2015-05-11 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
S - Sale | −1 215 | 141 805 | −0,85 | 8,02 | −9 744 | 1 137 276 | |
2015-05-11 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | 1 215 | 143 020 | 0,86 | 5,74 | 6 974 | 820 935 | |
2015-05-08 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Non-Qualified Stock Option (right to buy) |
A - Award | 3 861 | 3 861 | |||||
2015-05-08 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Deferred Stock Unit |
A - Award | 342 | 669 | 104,59 | ||||
2015-05-05 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −10 647 | 1 215 | −89,76 | 5,74 | −61 114 | 6 974 | |
2015-05-05 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | 10 647 | 141 805 | 8,12 | 5,74 | 61 114 | 813 961 | |
2015-05-05 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −35 315 | 11 862 | −74,86 | 5,74 | −202 708 | 68 088 | |
2015-05-05 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
S - Sale | −35 315 | 131 158 | −21,21 | 8,36 | −295 198 | 1 096 350 | |
2015-05-05 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | X | 35 315 | 166 473 | 26,93 | 5,74 | 202 708 | 955 555 |
2015-05-04 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
A - Award | 40 | 540 | 8,00 | 125,37 | 5 015 | 67 700 | |
2015-04-22 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −6 969 | 47 177 | −12,87 | 5,74 | −40 002 | 270 796 | |
2015-04-22 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | 6 969 | 131 158 | 5,61 | 5,74 | 40 002 | 752 847 | |
2015-04-06 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −26 132 | 54 146 | −32,55 | 5,74 | −149 998 | 310 798 | |
2015-04-06 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | 26 132 | 124 189 | 26,65 | 5,74 | 149 998 | 712 845 | |
2015-02-18 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Non-Qualified Stock Option (right to buy) |
A - Award | 449 | 449 | |||||
2015-02-18 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Deferred Stock Unit |
A - Award | 37 | 327 | 12,76 | ||||
2014-09-22 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −17 421 | 76 278 | −18,59 | 5,74 | −99 997 | 437 836 | |
2014-09-22 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | 17 421 | 98 057 | 21,60 | 5,74 | 99 997 | 562 847 | |
2014-07-18 |
|
4 | IMGN |
IMMUNOGEN INC
Stock option (right to buy) |
A - Award | 205 000 | 205 000 | 10,79 | 2 211 950 | 2 211 950 | ||
2014-05-09 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Non-Qualified Stock Options (right to buy) |
A - Award | 2 987 | 2 987 | |||||
2014-05-09 |
|
4 | IDXX |
IDEXX LABORATORIES INC /DE
Deferred Stock Unit |
A - Award | 290 | 290 | |||||
2014-03-18 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −15 000 | 97 699 | −13,31 | 5,74 | −86 100 | 560 792 | |
2014-03-18 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
S - Sale | −15 000 | 80 636 | −15,68 | 16,40 | −246 000 | 1 322 430 | |
2014-03-18 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | 15 000 | 95 636 | 18,60 | 5,74 | 86 100 | 548 951 | |
2014-03-14 | 3 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
1 000 | ||||||||
2014-03-14 | 3 | IDXX |
IDEXX LABORATORIES INC /DE
Common Stock |
1 000 | ||||||||
2014-02-20 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −15 000 | 112 699 | −11,75 | 5,74 | −86 100 | 646 892 | |
2014-02-20 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
S - Sale | −15 000 | 80 636 | −15,68 | 16,26 | −243 922 | 1 311 262 | |
2014-02-20 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | 15 000 | 95 636 | 18,60 | 5,74 | 86 100 | 548 951 | |
2013-12-27 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −7 300 | 127 699 | −5,41 | 5,74 | −41 902 | 732 992 | |
2013-12-27 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | 7 300 | 80 636 | 9,95 | 5,74 | 41 902 | 462 851 | |
2013-12-12 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −15 000 | 134 999 | −10,00 | 5,74 | −86 100 | 774 894 | |
2013-12-12 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
S - Sale | −15 000 | 73 336 | −16,98 | 15,11 | −226 695 | 1 108 327 | |
2013-12-12 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | 15 000 | 88 336 | 20,45 | 5,74 | 86 100 | 507 049 | |
2013-09-05 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −16 667 | 149 999 | −10,00 | 5,74 | −95 669 | 860 994 | |
2013-09-05 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
S - Sale | −16 667 | 73 336 | −18,52 | 16,43 | −273 772 | 1 204 617 | |
2013-09-05 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | X | 16 667 | 90 003 | 22,73 | 5,74 | 95 669 | 516 617 |
2013-08-02 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −16 667 | 166 666 | −9,09 | 5,74 | −95 669 | 956 663 | |
2013-08-02 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
S - Sale | −16 667 | 73 336 | −18,52 | 19,21 | −320 140 | 1 408 638 | |
2013-08-02 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | X | 16 667 | 90 003 | 22,73 | 5,74 | 95 669 | 516 617 |
2013-07-17 |
|
4 | IMGN |
IMMUNOGEN INC
Stock option (right to buy) |
A - Award | 205 000 | 205 000 | 19,02 | 3 899 100 | 3 899 100 | ||
2013-07-05 |
|
4 | IMGN |
IMMUNOGEN INC
Stock Option (right to buy) |
M - Exercise | −16 667 | 183 333 | −8,33 | 5,74 | −95 669 | 1 052 331 | |
2013-07-05 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
S - Sale | −16 667 | 73 336 | −18,52 | 17,31 | −288 529 | 1 269 549 | |
2013-07-05 |
|
4 | IMGN |
IMMUNOGEN INC
Common Stock |
M - Exercise | X | 16 667 | 90 003 | 22,73 | 5,74 | 95 669 | 516 617 |
2012-07-23 |
|
4 | IMGN |
IMMUNOGEN INC
Stock option (right to buy) |
A - Award | 180 000 | 180 000 | 15,83 | 2 849 400 | 2 849 400 | ||
2008-06-13 |
|
4 | IMGN |
IMMUNOGEN INC
Incentive stock option (right to buy) |
A - Award | 23 333 | 23 333 | 3,30 | 76 999 | 76 999 | ||
2008-06-13 |
|
4 | IMGN |
IMMUNOGEN INC
Non-qualified stock option (right to buy) |
A - Award | 46 667 | 46 667 | 3,30 | 154 001 | 154 001 |